-
Cosmo & Ferring Pharmaceuticals enter into licensing agreement for CORTIMENT®MMX® (budesonide) in Japan
-Cosmo Pharmaceuticals S.A. (SIX: COPN) announced today that it has signed a licensing agreement with Ferring Pharmaceuticals…
-
Ferring Pharmaceuticals submits variation application to introduce new tailored dosing regimen in the PICOPREP® (sodium picosulfate, magnesium oxide, citric acid) label
-Ferring Pharmaceuticals announced today that it has submitted a variation application in the Mutual Recognition…
-
Ferring receives acceptance of Marketing Authorisation filing from EMA for personalised fertility treatment with REKOVELLE® (follitropin delta)
-Ferring Pharmaceuticals announced today that the filing for the Marketing Authorisation Application for…
-
Ferring Pharmaceuticals acquires global rights to MILPROSA (progesterone vaginal ring)
-Ferring Pharmaceuticals announced today that it has acquired the global rights to MILPROSATM (progesterone vaginal ring) from Teva Women’s…
-
Ferring Pharmaceuticals begins Phase 2b/3 trial of selepressin for treatment of septic shock
-Ferring Pharmaceuticals announced initiation of patient enrollment in a phase 2b/3 clinical trial of selepressin for the treatment of septic shock…
-
Ferring Pharmaceuticals moves forward with early stage development of bacteriophage therapy for inflammatory bowel disease
-Ferring Pharmaceuticals announced today that it will collaborate with Baltimore-based Intralytix, Inc…
-
Inflammatory Bowel Disease Treatment Gets Boost From New Educational Resource
-A new educational resource for doctors and healthcare professionals will help improve knowledge and treatment of Inflammatory Bowel Disease (IBD)…
-
Ferring and the Institut Pasteur collaborate in novel IBD drug development project
-Ferring Pharmaceuticals a research-driven, specialty biopharmaceutical group and the Institut Pasteur, a non-profit international biomedical…
-
Ferring announces European approval of new room temperature stable formulation of PABAL® (carbetocin)
-Ferring announced today that its new room-temperature-stable* formulation of PABAL® (carbetocin) for intravenous (IV) administration…
-
Ferring Pharmaceuticals acquires novel drug delivery technology from CTCBIO Inc.
-Ferring Pharmaceuticals announced today that it has signed an agreement with CTCBIO Inc. of Seoul, South Korea to acquire rights to…
PRESS RELEASE 2015
PRESS RELEASE 2015